<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242281</url>
  </required_header>
  <id_info>
    <org_study_id>111.302</org_study_id>
    <nct_id>NCT00242281</nct_id>
  </id_info>
  <brief_title>APC-111 MP Tablet Once a Day vs.Penicillin VK Four Times a Day Both for 10 Days in Patients With Strep Throat</brief_title>
  <official_title>A Phase III, Multicenter Study to Evaluate the Safety/Efficacy of APC-111 MP Tablet QD vs. Penicillin VK QID Both for 10 Days Treatment of Pharyngitis Secondary to S.Pyogenes in Adolescents/Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advancis Pharmaceutical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advancis Pharmaceutical Corporation</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of APC 111 MP Tablet, 775 mg&#xD;
      tablet, given orally (PO)once daily (QD) for 10 days compared to that of Penicillin VK, 250&#xD;
      mg PO four times daily (QID) for 10 days in terms of bacteriological outcome at the&#xD;
      Test-of-Cure (TOC) Visit (Day 14-18) in the eligible Per-Protocol bacteriological (PPb)&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date>July 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The bacteriological outcome at the Test - of - Cure Visit (Day 14-18)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The bacteriological outcome at the Late Post Therapy visit (Day 38-45)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome at TOC and LPT</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment>600</enrollment>
  <condition>Sore Throat</condition>
  <condition>Pharyngitis</condition>
  <condition>Tonsillitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APC-111 MP Tablet, 775 mg</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent/assent&#xD;
&#xD;
          -  Age 12 and older&#xD;
&#xD;
          -  A clinical diagnosis of acute tonsillitis and/or pharyngitis defined as having the&#xD;
             clinical signs and symptoms compatible with tonsillitis and/or pharyngitis, including&#xD;
             sore throat and pharyngeal erythema with at least one of the following:&#xD;
&#xD;
               -  Odynophagia&#xD;
&#xD;
               -  Tonsillar or pharyngeal exudates&#xD;
&#xD;
               -  Tender cervical lymph nodes&#xD;
&#xD;
               -  Fever or history of fever treated with antipyretics&#xD;
&#xD;
               -  Chills&#xD;
&#xD;
               -  Uvular edema&#xD;
&#xD;
               -  Elevated white blood cell count&#xD;
&#xD;
               -  Red tongue and prominent papillae&#xD;
&#xD;
          -  A positive rapid screening test for S. pyogenes&#xD;
&#xD;
          -  Subject is an appropriate candidate for oral antibiotic therapy and can swallow the&#xD;
             study dosage forms&#xD;
&#xD;
          -  Females must be non-lactating and:&#xD;
&#xD;
               -  At no risk of pregnancy for one of the following reasons: post-menopausal for at&#xD;
                  least one year, hysterectomy, tubal ligation, or abstinent from sexual activity&#xD;
                  that could result in pregnancy, OR&#xD;
&#xD;
               -  If of child-bearing potential and sexually active, the patient must have a&#xD;
                  negative baseline urine pregnancy test and be utilizing acceptable contraceptives&#xD;
                  throughout the study.&#xD;
&#xD;
               -  If of child bearing potential and not currently sexually active, the patient must&#xD;
                  have a negative baseline urine pregnancy test and must agree to remain abstinent&#xD;
                  for the duration of the study. If they decide to become sexually active during&#xD;
                  the period of the study, they must agree to use acceptable contraception.&#xD;
&#xD;
          -  Are able to comply with the requirements of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic or recurrent odynophagia or enlarged tonsils of obscure etiology&#xD;
&#xD;
          -  More than one episode of acute tonsillitis and/or pharyngitis in the 6 months prior to&#xD;
             baseline visit&#xD;
&#xD;
          -  Pharyngitis known or suspected to be due to a pathogen resistant to β-lactam&#xD;
             antimicrobials&#xD;
&#xD;
          -  Subjects who are known carriers of S. pyogenes&#xD;
&#xD;
          -  Previous allergies, serious adverse reaction to, or intolerance to penicillin or any&#xD;
             other member of the β-lactam class of antimicrobials, including cephalosporins&#xD;
&#xD;
          -  Any serious illness or concomitant condition that the Investigator judges would&#xD;
             preclude the study evaluations or make it unlikely that the course of study therapy&#xD;
             and follow-up could be completed. This would also include:&#xD;
&#xD;
               -  Any rapidly progressive underlying disease with a shortened life expectancy&#xD;
&#xD;
               -  The inability to swallow the study dosage form&#xD;
&#xD;
               -  Unable to understand the requirements of the study&#xD;
&#xD;
               -  Neutropenia (&lt;1000 PMNs/mm3) or other immunocompromised state.&#xD;
&#xD;
          -  Concurrent condition of upper/lower respiratory tract infections&#xD;
&#xD;
          -  Concurrent symptoms of viral etiology including:&#xD;
&#xD;
               -  conjunctivitis, coryza, and cough&#xD;
&#xD;
               -  diffuse adenopathy or rash suggestive of mononucleosis&#xD;
&#xD;
               -  rash or arthropathy suggestive of scarlet fever&#xD;
&#xD;
          -  Seizure disorder, lowered seizure threshold, or psychiatric condition requiring use of&#xD;
             major tranquilizers&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  Expectation that additional effective systemic antibacterials would be required for&#xD;
             any condition during the duration of the study&#xD;
&#xD;
          -  Current drug or alcohol abuse&#xD;
&#xD;
          -  Receipt of any experimental drug or medical device within the previous 30 days&#xD;
&#xD;
          -  Previous treatment under this protocol&#xD;
&#xD;
          -  The need for hospitalization or I.V. antimicrobial therapy&#xD;
&#xD;
          -  Previous systemic antimicrobial therapy within 30 days&#xD;
&#xD;
          -  The presence of clinically significant hematologic conditions&#xD;
&#xD;
          -  History of cardiovascular disease, renal disease, or neurological disease secondary to&#xD;
             previous infection with S. pyogenes or previous rheumatic fever&#xD;
&#xD;
          -  Probenecid treatment or systemic steroids for 7 days prior to baseline visit and&#xD;
             throughout the duration of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan P Clausen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Advancis Pharmaceutical Corp</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallassee</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laguna Niguel</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Conyers</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichitia</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Bedford</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simpsonville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canfield</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Wales</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scotland</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shippensburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonds</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Erie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Jermone</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2006</verification_date>
  <study_first_submitted>October 18, 2005</study_first_submitted>
  <study_first_submitted_qc>October 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2005</study_first_posted>
  <last_update_submitted>October 23, 2006</last_update_submitted>
  <last_update_submitted_qc>October 23, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2006</last_update_posted>
  <keyword>Sore Throat</keyword>
  <keyword>Pharyngitis</keyword>
  <keyword>Tonsillitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharyngitis</mesh_term>
    <mesh_term>Tonsillitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

